GlassScriptPhysician profile
Itrat Zehra
NPI 1275200271
$4,887.39
in general payments reported to CMS, 2019-2025
39 companies · $2,178 in 2025
The $2,178 reported for 2025 was more than what 95% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $15.86 · 2023: $1,081 · 2024: $1,612 · 2025: $2,178.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,862 · Education: $9.65.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,861.88 |
| Education | $9.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,052.20 | 2023-2025 | |
| Lundbeck LLC | $635.91 | 2023-2025 | Vyepti |
| Emd Serono, INC. | $446.81 | 2023-2025 | Mavenclad |
| Sk Life Science, INC. | $328.63 | 2024-2025 | Xcopri |
| Alexion Pharmaceuticals, INC. | $188.95 | 2023-2025 | Ultomiris |
| Biogen, INC. | $181.01 | 2023-2025 | Tysabri, Vumerity, Leqembi |
| Csl Behring | $175.07 | 2023-2025 | Hizentra |
| Celgene Corporation | $169.63 | 2023-2025 | Zeposia |
| Genentech USA, INC. | $162.14 | 2023-2025 | Ocrevus, Ocrevus Zunovo, Enspryng |
| Lilly USA, LLC | $139.75 | 2023-2025 | Emgality, Kisunla, Reyvow |
| Alnylam Pharmaceuticals INC. | $134.93 | 2023-2025 | Onpattro, Givlaari |
| Pfizer INC. | $131.88 | 2023-2025 | |
| Eisai INC. | $121.45 | 2023-2025 | |
| Catalyst Pharmaceuticals, INC. | $93.25 | 2024-2025 | |
| Averitas Pharma INC. | $83.69 | 2023-2025 | Qutenza |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $72.73 | 2024-2025 | Uplizna |
| Ani Pharmaceuticals, INC. | $65.64 | 2023-2025 | Purified Cortrophin Gel |
| Teva Pharmaceuticals USA, INC. | $60.86 | 2024-2025 | Austedo Xr, Austedo Xr |
| Ucb, INC. | $58.24 | 2023-2025 | Rystiggo, Zilbrysq |
| Argenx US, INC. | $57.02 | 2025 | Vyvgart Hytrulo |
| Otsuka America Pharmaceutical, INC. | $55.55 | 2024 | Nuedexta, Rexulti |
| Tg Therapeutics, INC. | $49.12 | 2025 | |
| Vanda Pharmaceuticals INC. | $40.40 | 2024 | Ponvory |
| Grifols USA, LLC | $39.46 | 2025 | Gamunex-C |
| Medtronic, INC. | $36.39 | 2023 | Intellis Adaptivestim |
| Kyowa Kirin, INC. | $34.44 | 2024 | Nourianz |
| Xeris Pharmaceuticals, INC. | $31.86 | 2025 | Keveyis |
| Cycle Pharmaceuticals INC | $30.44 | 2025 | Tascenso Odt, Bafiertam |
| Neurelis, INC. | $28.49 | 2024-2025 | Valtoco |
| Octapharma USA, INC. | $26.80 | 2025 | Panzyga |
| Mallinckrodt Hospital Products INC. | $22.81 | 2025 | Acthar |
| Acorda Therapeutics, INC | $21.04 | 2024 | Ampyra, Inbrija |
| Axsome Therapeutics, INC. | $18.22 | 2023 | Sunosi |
| Takeda Pharmaceuticals U.S.A., INC. | $17.47 | 2024 | Hyqvia |
| Ipsen Biopharmaceuticals, INC | $17.03 | 2024 | Dysport |
| Qol Medical, LLC | $15.86 | 2022 | |
| Insightec,INC | $14.66 | 2024 | Exablate |
| Mylan Specialty L.P. | $14.40 | 2024 | Glatiramer Acetate |
| Amneal Pharmaceuticals LLC | $13.16 | 2023 | Lyvispah |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Itrat Zehra listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.